In order to promote the sustainable development of nuclear energy through thorium (Th(IV)) recycling, we synthesized SiO-coated magnetic functional nanocomposites (SiO@FeO) that were modified with 2,9-diamide-1,10-phenanthroline (DAPhen) to serve as an adsorbent for Th(IV) removal. SiO@FeO-DAPhen showed effective Th(IV) adsorption in both weakly and strongly acidic solutions. Owing to its porous structure that facilitated rapid adsorption kinetics, equilibrium was achieved within 5 and 0.5 min at pH 3 and 1 mol L HNO, respectively. In weakly acidic solutions, Th(IV) primarily formed chemical coordination bonds with DAPhen groups, while in strongly acidic solutions, the dominant interaction was electrostatic attraction. Density functional theory (DFT) calculations indicated that electrostatic attraction was weaker compared to chemical coordination, resulting in reduced diffusion resistance and consequently faster adsorption rates in strongly acidic solutions. Furthermore, SiO@FeO-DAPhen exhibited a high adsorption capacity for Th(IV); it removed Th(IV) through chelation and electrostatic attraction at pH 3 and 1 mol L HNO, with maximum adsorption capacities of 833.3 and 1465.7 mg g, respectively. SiO@FeO-DAPhen also demonstrated excellent tolerance to salinity, adsorption selectivity, and radiation resistance, thereby highlighting its practical potential for Th(IV) removal in diverse contaminated water sources. Hence, SiO@FeO-DAPhen represents a promising choice for the rapid and efficient removal of Th(IV).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.inorgchem.3c02044 | DOI Listing |
Mol Pharm
January 2025
Department of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States.
Lumefantrine (LMF) is a low-solubility antimalarial drug that cures acute, uncomplicated malaria. It exerts its pharmacological effects against erythrocytic stages of spp. and prevents malaria pathogens from producing nucleic acid and protein, thereby eliminating the parasites.
View Article and Find Full Text PDFChem Commun (Camb)
January 2025
Department of Chemistry, Bar-Ilan University, Ramat-Gan 5290002, Israel.
Modified nucleosides are vital in mRNA vaccines. We developed a contracted uridine analog, N1-hydantoinyl-ribose, HR, using steric shields to invert the regioselectivity of the classic Vorbrüggen reaction. We report synthetic routes and explore HR features such as acidity, stability, base pairing/stacking, and crystal/solution conformation compared to uridine.
View Article and Find Full Text PDFAcc Chem Res
January 2025
State Key Laboratory of Physical Chemistry of Solid Surfaces, Key Laboratory of Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, and Discipline of Intelligent Instrument and Equipment, Xiamen University, Xiamen 361005, P. R. China.
ConspectusMolecular photoelectrocatalysis, which combines the merits of photocatalysis and organic electrosynthesis, including their green attributes and capacity to offer novel reactivity and selectivity, represents an emerging field in organic chemistry that addresses the growing demands for environmental sustainability and synthetic efficiency. This synergistic approach permits access to a wider range of redox potentials, facilitates redox transformations under gentler electrode potentials, and decreases the use of external harsh redox reagents. Despite these potential advantages, this area did not receive significant attention until 2019, when we and others reported the first examples of modern molecular photoelectrocatalysis.
View Article and Find Full Text PDFJ Phys Chem A
January 2025
Ufa Institute of Chemistry, Ufa Federal Research Centre of the Russian Academy of Sciences, Laboratory of Physicochemical Methods of Analysis, 69 Prospekt Oktyabrya, Ufa 450054, Russian Federation.
The first-stage acid-base equilibrium of 5,5,6-trihydroxy-6-methyldihydropyrimidine-2,4(1,3)-dione was studied for the first time in aqueous solutions. Its constant (pK = 9.23 ± 0.
View Article and Find Full Text PDFDrug Des Devel Ther
January 2025
Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (Luvacs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden, the Netherlands.
Recently, avacopan has been approved for the treatment of ANCA-associated vasculitis (AAV). Avacopan is an inhibitor of the C5a-receptor, which plays an important role in chemotaxis and the amplification loop of inflammation in AAV. In the most recent, international guidelines avacopan is recommended as steroid-sparing agents for the management of AAV.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!